Cybin Completes Overnight Marketed Public Offering of Units

On August 4, 2023, Cybin Inc. (NEO:CYBN) (NYSE American: CYBN) (the “Company” or “Cybin”), a clinical-stage biopharmaceutical company committed to revolutionizing mental health care by developing new and innovative psychedelic-based treatment options, announced the closing of its previously announced overnight marketed public offering. In connection with the offering, Cybin issued an aggregate of 24,264,706 units of the Company (the “Units”) at a price of US$0.34 per Unit for aggregate gross proceeds of US$8.25 million.

Each Unit is comprised of one common share in the capital of the Company and one common share purchase warrant. The offering was conducted by Cantor Fitzgerald & Co., as the sole book-running manager, on an underwritten overnight marketed basis. A.G.P./Alliance Global Partners acted as lead manager for the offering.  

Cybin intends to use the net proceeds from the offering for the progression of the Company’s CYB003 and CYB004 programs, and for general corporate and working capital purposes.

Aird & Berlis represented Cybin with a team led by Sherri Altshuler and including Adria Leung Lim, Amy Marcen-Gaudaur, Sean Green and Meredith McCann (Capital Markets).